Compare GETY & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | PRTC |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.6M | 464.3M |
| IPO Year | N/A | N/A |
| Metric | GETY | PRTC |
|---|---|---|
| Price | $1.33 | $18.69 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.01 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 3.2K |
| Earning Date | 03-16-2026 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $946,327,000.00 | $6,391,000.00 |
| Revenue This Year | $2.64 | N/A |
| Revenue Next Year | $2.95 | N/A |
| P/E Ratio | ★ N/A | $8.66 |
| Revenue Growth | 3.10 | ★ 1265.60 |
| 52 Week Low | $1.20 | $13.30 |
| 52 Week High | $3.21 | $20.00 |
| Indicator | GETY | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 55.46 |
| Support Level | $1.23 | $18.60 |
| Resistance Level | $1.33 | $19.33 |
| Average True Range (ATR) | 0.05 | 0.70 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 86.36 | 57.88 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.